- Home
- FCF vs MLTX Comparison
FCF vs MLTX Comparison
Compare FCF & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCF | MLTX |
|---|---|---|
| Founded | 1934 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | 130 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FCF | MLTX |
|---|---|---|
| Price | $20.37 | $19.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $19.75 | ★ $27.50 |
| AVG Volume (30 Days) | 687.0K | ★ 1.2M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | ★ 5.76 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.32 | N/A |
| Revenue Next Year | $6.25 | N/A |
| P/E Ratio | $55.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.00 | $5.95 |
| 52 Week High | $20.47 | $62.75 |
Technical Indicators
Market Signals| Indicator | FCF | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 69.10 | 55.27 |
| Support Level | $18.07 | $15.54 |
| Resistance Level | N/A | $21.00 |
| Average True Range (ATR) | 0.36 | 1.18 |
| MACD | 0.08 | 0.12 |
| Stochastic Oscillator | 84.37 | 44.20 |
Price Performance
Historical ComparisonAbout FCF First Commonwealth Financial Corporation
First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.